Vogt-Koyanagi-Harada disease (VKHD): pathology

Evidence-based neurology checklist on vogt-koyanagi-harada disease (vkhd): pathology: Pathology This is an autoimmune disease The target are melanocyte antigens There is an HLA DR4 predisposition Triggers Risk populations Demographic features Clinical phases

Pathology

  • This is an autoimmune disease
  • The target are melanocyte antigens
  • There is an HLA DR4 predisposition

Triggers

Risk populations

Demographic features

Clinical phases

References

  1. Lavezzo MM, Sakata VM, Morita C, et al. Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes. Orphanet J Rare Dis 2016; 11:29.
  2. Sood AB, O'Keefe G, Bui D, Jain N. Vogt-Koyanagi-Harada disease associated with hepatitis B vaccination. Ocul Immunol Inflamm 2019; 27:524-527.
  3. Yoshino N, Kawamura A, Ishii A, et al. Vogt-Koyanagi-Harada disease associated with influenza A virus infection. Intern Med 2018; 57:1661-1665. 
  4. Dogan B, Erol MK, Cengiz A. Vogt-Koyanagi-Harada disease following BCG vaccination and tuberculosis. Springerplus 2016; 5:603. 
  5. Tieger MG, Eliott D, Cakir B, Dahrouj M. Checkpoint Inhibitor-Associated Vogt-Koyanagi-Harada disease presenting 3 months following discontinuation of nivolumab. Ophthalmic Surg Lasers Imaging Retina 2023; 54:183-187. 
  6. And 5 more. Subscribe to see the full list

Related checklists

Loading...